Page 1060 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 59 Clinical Manifestations and Treatment of Acute Myeloid Leukemia 943

17. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose with vosaroxin plus cytarabine versus placebo plus cytarabine: results
cytarabine and hydroxyurea with or without all-trans retinoic acid for of a phase 3 double-blind randomized controlled multinational study
acute myeloid leukemia and high-risk myelodysplastic syndrome in (VALOR). Blood 124:LBA–6, 2014.
patients not considered fit for intensive treatment. Cancer 109:1114, 24. Hills RK, Castaigne S, Appelbaum FR, et al: Addition of gemtuzumab
2007. ozogamicin to induction chemotherapy in adult patients with acute
18. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al: Azacitidine prolongs myeloid leukaemia: a meta-analysis of individual patient data from
overall survival compared with conventional care regimens in elderly randomized controlled trials. Lancet Oncol 15:986, 2014.
patients with low bone marrow blast count acute myeloid leukemia. J 25. Döhner H, Lübbert M, Fiedler W, et al: Randomized, phase 2 trial of
Clin Oncol 28:562, 2010. low-dose cytarabine with or without volasertib in AML patients not
19. Kantarjian HM, Thomas XG, Dmoszynska A, et al: Multicenter, ran- suitable for induction therapy. Blood 124:1426, 2014.
domized, open-label, phase III trial of decitabine versus patient choice, 26. Sanz MA, Martin G, Rayon C, et al: A modified AIDA protocol with
with physician advice, of either supportive care or low-dose cytarabine anthracycline-based consolidation results in high antileukemic efficacy
for the treatment of older patients with newly diagnosed acute myeloid and reduced toxicity in newly diagnosed PML/RARalpha-positive acute
leukemia. J Clin Oncol 30:2670, 2012. promyelocytic leukemia. PETHEMA group. Blood 94:3015, 1999.
20. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemo- 27. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic
therapy in adults with acute myeloid leukemia. Cancer and Leukemia trioxide for acute promyelocytic leukemia. N Engl J Med 369:111,
Group B. N Engl J Med 331:896, 1994. 2013.
21. Hills RK, Castaigne S, Appelbaum FR, et al: Addition of gemtuzumab 28. Powell BL, Moser B, Stock W, et al: Arsenic trioxide improves event-
ozogamicin to induction chemotherapy in adult patients with acute free and overall survival for adults with acute promyelocytic leukemia:
myeloid leukaemia: a meta-analysis of individual patient data from North American Leukemia Intergroup Study C9710. Blood 116:3751,
randomized controlled trials. Lancet Oncol 15:986, 2014. 2010.
22. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplanta- 29. Bakst RL, Tallman MS, Douer D, et al: How I treat extramedullary acute
tion for acute myeloid leukemia in first complete remission: systematic myeloid leukemia. Blood 118:3785, 2011.
review and meta-analysis of prospective clinical trials. JAMA 301:2349, 30. Thomas X: Acute myeloid leukemia in the pregnant patient. Eur J
2009. Haematol 95:124, 2015.
23. Ravandi F, Ritchie E, Sayar H, et al: Improved survival in patients
with first relapsed or refractory acute myeloid leukemia (AML) treated